BCOP Updates 2023: Treatment Updates in mCRPC: PSMA-Directed Therapy
Men with metastatic castration-resistant prostate cancer (mCRPC) have limited treatment options. Prostate-specific membrane antigen (PSMA) is expressed in >80% of men with mCRPC. PluvictoTM (Lutetium Lu-177 vipivotide tetraxetan) is the first FDA-approved targeted radioligand treatment which combines a targeting ligand with a therapeutic radiaoactive particle for the treatment of mCRPC in adults who have been treated with androgen receptor pathway inhibition and taxane-based chemotherapy. Lu-177-PSMA-617 radionucleotide therapy has demonstrated significant improvement in overall survival (OS) and progression-free survival (PFS). With its novel mechanism of action and proven efficacy, Lu-177-PSMA-617 promises to change the treatment landscape in prostate cancer.
In this module, participants will review treatment options for mCRPC, with a focus on PSMA-directed therapy. This session will describe the novel mechanism of action of Lu-177-PSMA-617 and analyze key literature leading to its FDA-approval with an emphasis on safety and efficacy. At the end of this session, participants will be able to identify the role of Lu-177-PSMA-617 in the treatment of mCRPC and understand dosing/administration and access considerations for this treatment option. This session will also review monitoring parameters and side effect management for PSMA-directed therapy.